Volume 28, No 3, Mar 2018

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 28 Issue 3, March 2018: 263-264

RESEARCH HIGHLIGHTS

Anti-PD1 in the wonder-gut-land

Marie Vetizou¹, Giorgio Trinchieri¹

¹Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Correspondence: Giorgio Trinchieri(E-mail: trinchig@niaid.nih.gov)

After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.

10.1038/cr.2018.12

FULL TEXT | PDF

Browse 780